StockDrifts LogoStockDrifts

Hyundai Bio 048410

Company
현대바이오Hyundai Bio
Insiders
0
Buys
0
Total Value
Avg Return
Last Filing
2025-12-15

Hyundai Bio (048410) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Hyundai Bio is dated 2025-02-27; the most recent is 2025-12-15. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-12-15SELL기타
씨앤팜
C&Farm
--560.0K₩5,220-240.4%₩2.9B ($2.0M)
2025-07-25BUY무상신주취득
씨앤팜
C&Farm
-5.1M₩6,320+181.2%₩32.2B ($22.4M)
2025-07-11SELL교환
씨앤팜
C&Farm
--479.6K₩6,960-155.3%₩3.3B ($2.3M)
2025-06-25SELL기타
씨앤팜
C&Farm
--258.9K₩4,605-285.9%₩1.2B ($828K)
2025-02-27BUY유상신주취득
오상기
Oh Sang-gi
CEO and President17.6K₩6,150+188.9%₩109M ($75K)
2025-02-27BUY유상신주취득
씨앤팜
C&Farm
-996.8K₩6,150+188.9%₩6.1B ($4.3M)
2025-02-27BUY유상신주취득
진근우
Jin Geun-woo
vice president4.1K₩6,150+188.9%₩25M ($18K)
2025-02-27BUY유상신주취득
조용호
Cho Yong-ho
thanks4.9K₩6,150+188.9%₩30M ($21K)

Frequently asked questions

Who has been buying Hyundai Bio stock?
0 distinct insiders have filed 0 disclosed insider purchases in Hyundai Bio (048410), most recently on 2025-12-15. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Hyundai Bio have?
Hyundai Bio has 0 buy-side and 0 sell-side disclosures on record, spanning 2025-02-27 to 2025-12-15.
Where does StockDrifts get Hyundai Bio insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Hyundai Bio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.